5-7 June 2018
Hilton Amsterdam,
Amsterdam, NL
Bringing you the latest science, technologies and partners needed to accelerate next generation antibodies towards commercial success
Brought to you by the same organizers of the trusted Antibody Engineering & Therapeutics conference in the US, in conjunction with the Antibody Society
Reserve your spot today so you can fast-track your antibody research to the clinic and beyond and collaborate with leading pharmas, biotechs, academic institutes and solution providers involved in antibody, protein and immunotherapeutic development. We look forward to welcoming you to Amsterdam.
Keynotes from the Foremost Authorities
Join 250+ of Your Colleagues from the Following Companies
AB Studio Inc
Ablynx
Ablynx NV
Adaptimmune Ltd
Aduro Biotech Europe
Aelian Biotechnology
AIMM Therapeutics
Amgen Research Munich GmbH
Amgen, Inc.
Antikor Biopharma Ltd
Aptevo Therapeutics
Argen-X N.V.
BioNTech
Boehringer Ingelheim
Boehringer Ingelheim Pharmaceutical Inc.
Celyad S.A.
CEPC, INSTITUT DE RECHERCHE PIERRE FABRE
Christian-Albrechts-University Kiel
ChromoTek GmbH
CHRU Besancon/ITAC platform
CRUK-MEDIMMUNE
CureVac AG
Elasmogen Ltd
EPO Berlin-Buch GmbH (EPO)
ErasmusMC
ESPCI
ETH Zurich
ETH Zurich/Swiss Federal Institute of Te
Experimental Biotherapeutics Centre
FairJourney Biologics
Garvan Institute of Medical Research
Genentech, Inc.
Genmab BV
Ghent University
Gilead Sciences
Ginkgo Bioworks
Goshen College
Gustave Roussy Cancer Centre
Institute of Molecular & Cell Biology
Iontas
Kagoshima University
Karolinska Institutet
Kookmin University
Kyowa Hakko
Kirin
LakePharma
Leiden University
Leiden University Medical Center
LifeArc
MedImmune
Nestle Skin Health
Nestle Skin Health/Galderma RandD
Novimmune SA
peptron
Prothix B.V.
Radboud Institute for Molecular Life Sci
Ragon Institute of MGH, MIT and Harvard
Roche Innovation Center Zurich
Sanofi
Sanofi Aventis R & D
Shemyakin and Ovchinnikov Institute of B
Specifica
Symphogen AS
Tagworks Pharmaceuticals
Taipei Medical University
Takis Srl
The Harley Street Clinic
The Netherlands Cancer Institute
TheraPharm Deutschland GmbH
Tohoku University
TU-Braunschweig, Dep. Biotechnology
UCB UCb Celltech
UCL Cancer Institute
UMC
Utrecht University College London
University Hospital of Erlangen
University Medical Center Hamburg-Eppend
University of Cologne
University of Oxford
University of Southampton
University of Zurich
Uppsala University
Utrecht University
WuXi Biologics
Y-mAbs Therapeutics, Inc.
YUMAB GmbH
Zymeworks Inc
By the Numbers
250+
50+
30+
Submit a Poster at Antibody Engineering & Therapeutics
Share your company's new research by presenting a poster at Antibody Engineering & Therapeutics Europe. Poster presenters may display their poster during 1 day of the conference – 6 June or 7 June Posters should be in PORTRAIT orientation and no larger than 1m wide x 1.5m high.
Please note that all poster presenters must be registered attendees.
The deadline to submit an abstract and be included in the conference documentation is Friday, 18 May 2018 (full payment for conference and poster fee must be received by this date). After that date, posters are on a space-available basis.
Become an Event Sponsor or Exhibitor
Showcase your products and services to antibody scientists and executives. To request a floor plan, or to see a list of available package options, please contact Aimee Croke at aimee.croke@knect365.com or +1-857-504-6697.
About The Antibody Society
The Antibody Society is an international, non-profit association representing individuals and organizations involved in antibody-related research and development. Our members serve as the Scientific Advisors for the Antibody Engineering & Therapeutics (US) and the Antibody Engineering & Therapeutics Europe conferences. To provide additional opportunities for education and networking, we contribute scientific content and financial support for other conferences that cover topics relevant to antibody R&D, and are hosted by non-profit organizations. We research and analyze data on targeted therapeutics developed by the biopharmaceutical industry, and distribute our results and opinion via the Society’s website, presentations and publications. The Society also engages with government and international agencies on matters of importance to the antibody community.
